Ahh a closet AMARINIAN ... welcome

I will do that right after I finish my tea leaf reading class ...

The Unicorns are getting their horns polished and the Sheroes have new trinkets

I would like to believe you but I dont think that is the case any longer . MAny politicians are being bought out by foreign governments something that would have never happened in the past . We had foreign entities contributing millions to Hillarys' foundation when she was secretary of state we have HUnter selling painting for half a million that look like a third grader was let loose with with a toothbrush - we have become a third world nation where the country is for sale

Good One Shadolane - will the unicorns stop running at 0 ?

WOnder when The offices in NJ will be shut down ? SOmeone should swing by and see if they are moving stuff out ?

and yet on 11/18 the inverted kangaroo tail pointed to it going higher

hmmm lets see if I predict the stock is going up and down I cant be wrong !!

I hope MARJAC wins but I think that is a remote possibility - yes the stock can go lower and essentially US operations will cease .... reps removed - HQ shut down in NJ - stock removed from US market ... all a possibility

AMRN the laughing "stock" of Wall street ....

https://www.marketbeat.com/instant-alerts/nasdaq-amrn-analyst-earnings-estimates-2022-01-2-3/


Amarin Co. plc (NASDAQ:AMRN) - Equities research analysts at Jefferies Financial Group raised their Q4 2021 earnings per share estimates for Amarin in a report issued on Friday, January 21st. Jefferies Financial Group analyst M. Yee now expects that the biopharmaceutical company will post earnings per share of $0.00 for the quarter, up from their previous estimate of ($0.01).

A number of other brokerages have also recently weighed in on AMRN. Zacks Investment Research raised shares of Amarin from a "hold" rating to a "strong-buy" rating and set a $4.00 price target on the stock in a research report on Wednesday, January 12th. SVB Leerink restated a "buy" rating and set a $12.00 price objective on shares of Amarin in a research note on Sunday, September 26th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Amarin currently has an average rating of "Buy" and an average target price of $8.20.

YES !!! WE hit $2.xx !!

Going to $2.xx penny stock sheets soon - AMRN tweeting about Sheroes riding unicorns in the daisies

Hmm do I buy at $2.xx right now I bought at $3.xx and $4.25 not good

one out of 50 is 2% REDUCE it was 25% reduction 1 out of 4

Couldn't agree more and this is where AMRN's marketing is so weak they should singing from the mountain tops that ezetimibe has NO OUTCOMES studies


do you want to give your patients something that you know works or something that might work !!!???

AMRN should be working with INsurers and AHA etc to insure their guidelines first use medications that are PROVEN to work not med that MIGHT work

but if they take an RX for Vastor and break it into say atorvastatin and gV that is direct confirmation of infringement - I remember having a long discussion here about that when I introduced VASTOR !!

The one point in this graph that would have to jump out to any person who has no knowledge of Vascepa but becomes familiar with indications etc is how can Lovaza with <1/10th the market share of V and gV have penetration that is 60% of V and gV ?

If lovaza has a market of 60k for 10% then V and gV should be 540K for 90%


So think about this gentleman and Lady ( Lizzy) - if Healthnet suit fails - if Marjac fails then either

1.) Vastor or

2.) WOUld it make sense to hash out a deal with gV - ask them to contribute to marketing and advertising and share this pie - even if they did a 50 50 split of expense and market share - AMRN woulD have 270K Rxs - thats a lot better than their current 75K and would represent an expansion of 260% ( head guesstimate)

V = 3500 new Rx's
L = 2600

Assuming VHT is only 10% of the RX;s one has to come to the conclusion that either

1.) LOvaza is penetrating the market for their 10% indication much more thoroughly than AMRN's penetration of a market that is easily 10 x larger. Yet there is no advertising that I see for Lovaza for trigs > 500 this is old information and not being actively pursued by any pharmaceutical firm that I am aware of or

2.) Lovaza is being prescribed for a CAD indication - a reflection on AMRN's poor job of education and intervention

gv = 1600 New Rx's

Once again

1.) gV is penetrating the market for VHT much better than V for CAD ? - yet how can this be - they perform no marketing -

2.) gV is directly infringing on the CAD market

WE can clearly say that 90% of AMRN's RX are for CAD indication.


gV has 1600 RX's - theoretically only for VHT with no advertising. AMRN then with no advertising but a 90% greater market V should have 14,400 new Rx's

Since gV has never performed any advertising for the VHT market - their only indication - how can one say that with no advertising gV penetrates the VHT market substantially more then AMRN penetrates the CAD market with some advertising ?

MUch prefer the snow but to each his own ...

So CRP is now officially the cause of CAD and therefore any drug that lowers CRP will automatically get approved for risk reduction? Its simply another marker

Thats the point it is a jest to play on NIssen -

Selective memory is a lot different than actively cropping a table

But wait .... cant we blame mineral oil .....

I suspect the good judge practices what she preaches and therefore her home's doors are wide open to any and everyone as having a home border would be racist as well ...

So Kiwi your premise is its ok to lie as long as you are not caught ?

AMRN couldn't sell heaters to Eskimos .....

I think someone asked this before and would welcome legal eagle opinion.

If Healthnet loses will they be responsible for damages from all RX's that infringe or just theirs ?

If its latter this probably doesn't even add up to their legal fees?

In that case wont they settle ?

Yet if they settle I dont see this giving AMRN much traction - sure they can go to each and every insurer and threaten to sue them - it will take forever and insurers will just keep pushing sticks between their legs... patents will run out before they get everyone on board.

It appears to me that Marjacs Hail Mary is our only chance and that is a slim one.

Thanks Capt!

Dear Jurist:

We have in front of us the case of a very small company who took a tremendous financial risk to seek scientific truth to improve the health of humankind. There was no guarantee that their endeavors would produce positive results and like many startups they they could have lost everything. Unlike many big pharmaceutical firms who are laden with cash and have numerous products - this startup company has one and only one medication upon which they risked everything. Like any inventor this small company thought its intellectual property would be protected by our patent system.



The irony here is that the patent system DOES Protect the utilization of this medication for the preventions an treatment of coronary disease.


Unfortunately , unscrupulous insurers have found a way to bypass these patents undermining all the efforts of this company literally destroying them in the process.

Ask yourself "Is this Fair?"

SAy you spent 10 years and your life savings developing a product that no one thought would work. You have proven them wrong and are now taking the next steps, spending and borrowing millions to establish manufacturing, advertising, trade representative and all the myriad of system that one must have to sell and distribute your product ... your life's dream. And now just when everything is about to come to fruition someone copies your idea having expended no time or money - they just steal your idea even though your patent says they cant by utilizing a
conniving wrinkle in the law

Do you think that is fair ? If so then you should find Healthnet not Guilty but if you think actions like this, stealing and undermining small start up companies, bypassing legal patents for their personal financial gain are morally and legally wrong then you should find for AMRN

The idea is to help the jurist be AMRN - would the jurist want this to happen to them or a family member - take it down to the personal level

GOing to be hard to eat a formula ....

Thanks TOSCA

here is a great reply from British Cardiovascular Society

Just an example of wha I receive daily ....

Hedge Funds and AMRN

https://finance.yahoo.com/news/amarin-corporation-plc-amrn-fell-171118152.html

That actually may be good - maybe KM is cleaning house. I felt my rep was doing little to nothing - I asked her about the 6 PA / rejections currently sitting in my inbox and she said "Yea they expect me to respond to the insurance companies but I dont have time"

This is why we need an advertising department asking the following ...


Vascepa reduces your risk of a cardiac event by 25%. If you are patient with known CAD or even a diabetic with risk factors and are not on Vascepa ...ask your Doctor why ?

Hmmmm.... Vastor ....seems I heard of that somewhere ...

Well at least this one is on Friday and at least AMRN is getting the word out -- wonder if BP will plant someone in their to try and take down the lecturers ---- paging Stevie paging Stevie

Its an INdustry Symposium on SATURDAY ...I am sure it will be well attended....

Hee hee - do I hear $2.xx ... yes indeed ! I may have to buy ....

I wonder if we hit $2.xx do they do a reverse split or is AMRN put in with penny stocks ... lol

I believe their website lists UK, Switzerland and NJ

Although the FDA believes that lowering LDL may prevent CAD they did not believe lowering tris would do the same hence the requirement for REDUCE IT after the ADCOM hearing